66th American Society of Hematology Annual Meeting and Exposition (ASH 2024)
Agios at ASH 2024
Agios will highlight the clinical progress of its two PK activators – mitapivat and tebapivat (AG-946) – in multiple rare blood disorders with high patient needs, including thalassemia, sickle cell disease and myelodysplastic syndromes.
In total, 16 presentations and publications led by Agios and external collaborators will be shared at ASH 2024.
Visit the company’s booth (#105) onsite.
Agios ASH 2024 Data Room & Resources
Agios ASH 2024 Data Room
View Agios- and collaborator-led presentations and publications shared at ASH 2024.
Medical & Scientific Resources
Access educational and scientific resources related to Agios’ investigational and approved medicines. This site is for healthcare professionals only.
PYRUKYND® (mitapivat)
Learn more about Agios’ FDA-approved PK activator. This site is for U.S. healthcare professionals only.
Rethink Thalassemia
Find out more about the subtypes of thalassemia, its risks and complications, and how to manage the disease. This site is for U.S. healthcare professionals only.
Know Pyruvate Kinase (PK) Deficiency
Access information on PK deficiency, disease burden, and importance of management. This site is for U.S. healthcare professionals only.
AGIOS-ALL-0032 12/24